National PBM Drug Monograph Azacitidine (Vidaza[™])

May 2005

VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel

Executive Summary:

- Azacitidine is a pyrimidine analog believed to exert its effects through hypomethylation of DNA, restoring normal function to tumor suppressor genes, and through direct cytotoxicity of abnormal hematopoietic cells.
- It is indicated for patients with the following myelodysplastic disease subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia requiring IV antibiotics or thrombocytopenia with clinical hemorrhage requiring platelet transfusions or RBC transfusions for anemia), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.
- In a randomized trial compared to best supportive care, azacitidine produced better responses, delayed time to treatment failure, delayed transformation to acute myelogenous leukemia, increased QoL scores, and eliminated transfusion requirements in patients achieving a CR or PR.
- In patients who crossed over to azacitidine, a CR or PR was seen in 14% of patients.
- Overall survival showed a trend towards the azacitidine arm that was not statistically significant, although the results are confounded by the high number of best supportive care patients who crossed over to azacitidine therapy.
- Azacitidine is administered as a subcutaneous dose at 75mg/m² per day for 7 days, and repeated every 28 days.
- The majority of adverse events were GI (nausea, vomiting, diarrhea), myelosuppression (leukopenia, thrombocytopenia, neutropenia), and injection site reactions.
- Myelosuppression was generally reversible and blood counts returned to normal in many patients by the next treatment cycle. At a minimum, blood counts should be monitored before each treatment cycle.
- For patients with profound blood count nadirs, a dose reduction table is provided.
- Assessment of cytopenias is difficult because MDS causes cytopenias in some patients. For
 patients starting therapy with a cytopenia, a table is provided to assess nadir blood counts on
 a relative basis based on percentage decreased from baseline.
- Renal impairment, likely to occur in the elderly, may increase adverse events due to decreased excretion of azacitidine and its metabolites and should be monitored carefully with each treatment cycle.

Introduction

The purposes of this monograph are to (1) evaluate the available evidence of safety, tolerability, efficacy, cost, and other pharmaceutical issues that would be relevant to evaluating azacitidine for possible addition to the VA National Formulary; (2) define its role in therapy; and (3) identify parameters for its rational use in the VA.

Pharmacology/Pharmacokinetics^{1,2,3}

Azacitidine is an analog of the pyrimidine nucleoside cytidine. It has two main mechanisms of action: 1) cytotoxicity from incorporation into RNA, inhibiting protein synthesis, and into DNA, inhibiting DNA synthesis and 2) inhibition of DNA methylation resulting in cell differentiation. Azacitidine was developed because of its antileukemic activity at high concentrations and its differentiation potential at low concentrations due to hypomethylation. Cytosine hypermethylation of genes plays a role in gene expression and is thought to be important in cell proliferation and maturation; it is frequently found in myelodysplastic syndrome (MDS), acute myelogenous leukemia, and other malignancies.

Table #1	Azacitidine Pharmacokinetics
Parameter	Azacitidine
Metabolism	Spontaneous hydrolysis in aqueous solutions and rapid deamination by cytidine deaminase
Elimination	Primarily renal (85% after IV dose, 50% after subcutaneous dose); <1% excreted in feces
Half-life	After subcutaneous injection mean plasma half-life is 41 \pm 8 minutes; Mean elimination half-life is 4 hours for both IV and subcutaneous dose
Bioavailability	Bioavailability after subcutaneous injection compared to IV injection is 89% based on AUC ratio of least square means Subcutaneous AUC _{0$\rightarrow\infty$} ng•h/mL = 960.53 ± 458.06 Intravenous AUC _{0$\rightarrow\infty$} ng•h/mL = 1044.26 ± 285.67

FDA Approved Indication(s) and Off-label Uses

Azacitidine is approved for initial therapy in patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts. refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.

Off-label uses: Acute Myelogenous Leukemia (AML)

Current VA National Formulary Alternatives

Currently, there is no alternative therapeutic agent for treatment of MDS. Current treatment standards are primarily supportive care unless the patient is eligible for a stem cell bone marrow transplant.

Dosage and Administration

Dosage in MDS: Starting dose of 75mg/m² subcutaneously daily for 7 days, repeat every 4 weeks. Patients should be premedicated with an antiemetic. About 50% of patients achieve control of nausea and vomiting with prochlorperazine, but use of an HT3 antagonist may be required.

> If no benefit after 2 cycles and no toxicity other than nausea and vomiting, dose may be increased to 100mg/m²

May 2005

<u>Cycles:</u> a minimum of 4 cycles is recommended to evaluate response, however complete or partial responses may require more than 4 cycles. Treatment cycles are continued as long as there is benefit.

Dose Adjustments:

Table #2: Dose Adjustment if Baseline (start of therapy) counts are: WBC \geq 3.0 X10⁹/L, ANC \geq 1.5 X10⁹/L, and platelets \geq 75 X 10⁹/L Based on Nadir Counts

Nadir	% Dose in the Next Course	
ANC (X10 ⁹ /L)	Platelets (X10 ⁹ /L)	
<0.5	<25	50%
0.5-1.5	25 – 50	67%
>1.5	>50	100%

Table #3: Dose Adjustment if Baseline counts are: WBC <3.0 X10⁹/L, ANC <1.5 X10⁹/L, or platelets <75 X10⁹/L Based on Nadir Counts and Bone Marrow Biopsy Cellularity at time of Nadir^{*}

<u>IF</u> WBC or Platelet nadir % decrease in counts from baseline is:	AND Bone Marrow Biopsy Cellularity at Time of Nadir (%)		
	30-60	15-30	<15
	<u>THEN</u> % Dose in Next Course		
50-75%	100	50	33
>75%	75	50	33

*If there has been improvement in differentiation (% of mature granulocytes is higher and ANC is higher than at onset of course) at the start of the next cycle, give the same dose as before. If the nadir has occurred as defined in the table, start the next course at 28 days only if both the WBC and platelet counts are >25% above the nadir count and rising. If not, reevaluate counts every 7 days. If counts have not increased at least 25% by day 42, treat with 50% of the scheduled dose.

Dose Adjustment for Renal Function:

Serum bicarbonate levels <20mEq/L – Reduce dose by 50% on the next course

Unexplained Elevations of BUN or serum creatinine – delay next course until values return to normal or baseline then reduce dose by 50% on next course

Safety in patients with hepatic impairment has not been studied.

<u>Use in Geriatric Patients:</u> In clinical trials more than half of the patients were over 65 years old. No differences in efficacy were observed in this population. No significant differences in observed adverse events in this subpopulation. Because azacitidine and its metabolites are excreted by the kidney, and geriatric patients may have reduced renal function, it is useful to carefully monitor renal function during therapy with azacitidine.

Preparation and Stability:

- 1. Reconstitute each 100mg vial with 4ml sterile water for injection to make a suspension containing 25mg/mL. Invert the vial 2-3 times and gently swirl to form a suspension.
- 2. Doses greater than 4mL (100mg) should be divided equally into two syringes.
- 3. The suspension may be held at Room Temperature for up to 1 hour before administration.

May 2005

4. For delayed administration, the suspension may be kept in the vial or syringe(s) at Refrigerated Temperatures (2°C - 8°C, 36°F - 46°F) for up to 8 hours if refrigerated immediately after reconstitution.

Administration:

1. Contents of syringes should be re-suspended by inverting 2-3 times and gently rolling the syringe in the hands for 30 seconds before injecting.

2. When injecting 2 syringes, inject into 2 separate sites. Rotate sites on the thigh, abdomen, or upper arm so that new injections are given at least one inch from an old injection site.

Efficacy 4.5

Efficacy Measures

Primary Endpoint is Response Rate

Table#4 Efficacy Parameters

Response	Site	Criteria
Complete Response (CR)	Marrow	<5% blasts
Duration ≥4 weeks	Peripheral Blood	Normal CBC if abnormal at baseline
		Absence of blasts in peripheral circulation
	Transfusions	None
Partial Response (PR)	Marrow	RA, RARS: no marrow requirements
Duration ≥4 weeks		RAEB, RAEB-T, CMMoL: ≥50% decrease in blasts; improvement of marrow dyspoiesis
	Peripheral Blood	≥50% restoration in the deficit from normal levels of baseline white cells, hemoglobin, and platelets if abnormal at baseline No blasts in peripheral circulation
		For CMMoL, if WBC is elevated at baseline, a ≥75% reduction in the excess count over the upper limit of normal
	Transfusions	None
Improved	Marrow	No requirements
	Peripheral Blood	Monolineage or bilineage response that does not meet criteria for PR
	Transfusions	≤50% of baseline requirements

Secondary Endpoints:

- 1. Time-to AML Transformation or Death
- 2. Time to Treatment Failure
- 3. Overall Survival

4. Quality of Life-1) EORTC QoL Questionnaire C30 (general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning); 2) Mental Health Inventory (anxiety, depression, positive affect, emotional ties, loss of behavioral and emotional control); 3) Patient's perspective of improvement in their condition using a VAS.

May 2005

Summary of efficacy findings

A randomized, multicenter, open-label trial compared the safety and efficacy of subcutaneous azacitidine plus best supportive care (BSC) with best supportive care alone in patients with any of the five subtypes of myelodysplastic syndromes. Patients with the refractory anemia (RA) and refractory anemia with ringed sideroblasts (RAEB) subtypes were included if they also met at least one of the following criteria: required RBC transfusions in the past 3 months, had platelet counts \leq 50,000 or with clinical bleeding requiring platelet transfusions, or were neutropenic (ANC< 1.0 x 10⁹/L) with infections requiring IV antibiotics.

Table #5 Primary Outcome

Result	AzaC	BSC	Cross-over
	N=99	N=92	N=49
CR	7%*	0%	10%
PR	16*	0	4
Improved	37*	5†	33
Total	60*	5	47
Trilineage			
Response	23	0	14

† all 5 patients had improved counts while transforming to AML

*differences in arms in CR rate (P=0.01), CR+PR (P<0.0001), CR+PR+improvement (P<0.0001)

Table #6 Secondary Outcomes

Event	AzaC	BSC	
TT initial response	64 days	-	
TT best response	93 days	-	
Duration of response	15 months	-	
TTF	9.1 mos*	3.8 mos	
TT AML or death	21 mos**	12 mos	
AML as first event	15%†	38%	
Overall survival	20 mos‡	14mos	

*P<0.0001, **P=0.007, †P=0.001

‡P=0.1

Table #7 Effect on RBC's and Platelets

Effect	AzaC	
RBC lineage response	51%	
Elimination of RBC transfusion	45%	
Reduce RBC transfusion by 50%	9%	
Platelet response	47%	
WBC response	40%	

Table #8 Quality of Life Analysis versus Best Supportive Care

QoL Parameter	P value
Fatigue	0.001
Dyspnea	0.0014
Physical function	0.002
Positive affect	0.0077
Psychological distress	0.015

- The first study to report a treatment for MDS is better than best supportive care when assessed by multiple endpoints
- Response to Azacitidine was independent of MDS classification.
- The first drug in MDS that delays and decreases the transformation to AML
- Increased Quality of Life (QoL) parameters in several physical function and psychological parameters versus best supportive care
- Approximately 53% of patients on best supportive care crossed over to receive azacitidine as per the trial design.

May 2005

- This crossover confounds the overall survival results, which favor azacitidine but did not reach statistical significance.
- A landmark analysis was performed to eliminate the effect of the BSC patients who crossed over to azacitidine. Survival in three patient subgroups was compared from a 6month landmark date. Patients initially randomized to azacitidine survived an additional 18 months versus 11 months for patients who never crossed over or crossed over after 6 months (p=0.03).
- Patients on azacitidine had an increase in the mean number of RBC transfusions during the first month of treatment. Patients with CR or PR, by definition, had an elimination of RBC and platelet transfusions. Of the patients in the improved category, 22% had an elimination of RBC transfusions and 16% had a decrease by 50% or greater in transfusion requirements.

Other Studies:

Subcutaneous Administration of azacitidine

CALGB 8921: Phase II trial to determine which subcategories of MDS would respond to subcutaneous azacitidine. Sixty-seven patients were evaluated. A CR was achieved in 12%, a PR in 12% and improvement in 28%.

An additional six uncontrolled trials have been published.

IV administration

CALGB 8421 used azacitidine as a continuous infusion over 7 days plus supportive care. A CR was seen in 12%, a PR in 25%, and improvement in 12%. One third required a dose reduction because of myelosuppression.

Additional small trials using IV azacitidine have been published.

For further details on the efficacy results of the clinical trials, refer to *Appendix: Clinical Trials* (page 14).

Adverse Events (Safety Data)

Table#9 : Adverse Events in ≥5% of patients

Event	Azacitidine (N=220)	Observation (N=92)
Nausea	70.5%	17.4
Anemia	69.5	64.1
Thrombocytopenia	65.5	45.7
Vomiting	54.1	5.4
Pyrexia	51.8	30.4
Leukopenia	48.2	29.3
Diarrhea	36.4	14.1
Fatigue	35.9	25
Injection site erythema	35	0
Constipation	33.6	6.5
Neutropenia	32.3	10.9
Ecchymosis	30.5	15.2
Cough	29.5	15.2
Dyspnea	29.1	12
Weakness	29.1	20.7
Rigors	25.5	10.9
Petechiae	23.6	8.7
Injection site pain	22.7	0
Arthralgia	22.3	3.3
Headache	21.8	10.9
Anorexia	22.3	6.5
Pain in limb	20	5.4
Pharyngitis	20	7.6
Back pain	18.6	7.6
Contusion	18.6	9.8

May 2005

Edem peripheral 18.6 10.9 Explana 18.6 4.3 Chest pain 16.4 5.4 Explicitaxis 16.4 4.3 Rebrie Neutropenia 16.4 4.3 Malgia 15.9 2.2 Weight decreased 15.9 10.9 Abdominal pain 15.5 13 Pallor 16.5 7.6 Nasopharnytits 14.4 6.7 Dispone exertional 14.4 6.7 Dyspine exertional 14.1 9.8 Insection 13.6 0 Appetite decreased 12.7 8.7 Fatque agravated 12.7 4.3 Hypokalemia 12.7 4.3 Purtus 12.3 12 Adominal tenderness 11.8 1.1 Depression 11.8 7.6 Productive cough 11.4 4.3 Insommia 10.9 5.4 Upper adominial pain 10.5 3.2	Dizziness	18.6	5.4
Eythema 16.8 4.3 Chest pain 16.4 9.8 Epistaxis 16.4 9.8 Epistaxis 16.4 4.3 Mysigia 15.9 2.2 Weight decreased 15.9 10.9 Abdominal pain 15.5 13 Palor 15.5 7.6 Nasopharyngtis 14.5 9.8 Skin lesion 14.5 9.8 Skin lesion 14.1 0.8 Dysnea exertional 14.1 0.8 Injection site truising 14.1 0.8 Injection site reaction 13.5 0 Appelle decreased 12.7 4.3 Appelle decreased 12.7 4.3 Hipokademia 11.8 7.6 Productive cough 11.4 4.3 Abdominal tendemess 11.8 7.6 Productive cough 11.4 4.3 Maisise 10.9 3.3 Preadmialendemeress 11.8 7.6 <td>Edema peripheral</td> <td>18.6</td> <td>10.9</td>	Edema peripheral	18.6	10.9
Chest pain 16.4 9.8 Febric Neutropenia 16.4 9.8 Febric Neutropenia 16.4 4.3 Wajdja 15.9 2.2 Weight decreased 15.9 10.9 Addominal pain 15.5 7.6 Nasopharyngits 14.5 3.3 Pitting dedma 14.5 9.8 Skin lesion 14.8 8.7 Dyspene exertional 14.1 0 Rash 14.1 0.3 Injection site reaction 13.6 0 Anxiety 13.2 3.3 Appetite decreased 12.7 4.3 URI 12.7 4.3 URI 12.7 4.3 URI 12.7 4.3 URI 12.7 4.3 Depression 11.8 7.6 Productive cough 11.4 4.3 Insornia 10.9 3.3 Predictive cough 10.5 3.7 Objeen adoonin	Erythema	16.8	4.3
Epitaxis 16.4 9.8 Perbile Neutropenia 16.4 4.3 Myalgia 15.9 2.2 Weight decreased 15.9 10.9 Abdominal pain 15.5 13 Palor 15.5 7.6 Nasopharyngits 14.5 9.8 Skin lesion 14.8 8.7 Dyspnee avertional 14.1 16.3 Injection site bruising 14.1 9.8 Injection site reaction 13.6 0 Anxiety 13.2 3.3 Appetite decreased 12.7 4.3 Hypokalemia 12.7 4.3 Hypokalemia 12.7 4.3 Pruftus 12.3 12 Adominal Indermess 11.8 1.1 Depression 11.8 1.1 Productive cough 11.4 4.3 Insormia 10.9 5.4 Upper abdominal pain 10.5 8.7 Sweating increased 10.5 8.7	Chest pain	16.4	5.4
Febrie Neutropenia 16.4 4.3 Weigh decreased 15.9 2.2 Weigh decreased 15.9 10.9 Abdominal pain 15.5 13 Pallor 15.5 7.6 Nasopharynglis 14.5 3.3 Pitting adema 14.5 9.8 Skin lesion 14.8 8.7 Dyspnea exertional 14.1 10 Injection site bruing 14.1 0 Rash 14.1 0 Rash 14.1 0 Rash 14.1 0 Anxity 13.2 3.3 Appetite decreased 12.7 8.7 Fatuge aggravated 12.7 4.3 UR 12.3 12 Abdominal tenderness 11.8 7.6 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 4.3 Dyper abdominal pain 10.5 3.3 Cr	Epistaxis	16.4	9.8
Myalgia 15.9 2.2 Weight decreased 15.9 10.9 Abdominal pain 15.5 13 Palor 15.5 7.6 Nasophayngits 14.5 3.3 Pitting adema 14.5 9.8 Skin lesion 14.1 16.3 Dyspnea exertional 14.1 9.8 Injection site bruising 14.1 9.8 Injection site reaction 13.6 0 Anxety 13.2 3.3 Appetite decreased 12.7 4.3 Hypokalemia 12.7 4.3 Pruftus 12.3 12 Addominal tenderness 11.8 1.1 Depression 11.8 1.1 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Productive cough 11.4 4.3 Insomnia 10.9 5.4 Upper abdominal pain 10.5 8.7 Sweating increased 10.5 8.7<	Febrile Neutropenia	16.4	4.3
Weight decreased 15.9 10.9 Abdominal pain 15.5 13 Palor 15.5 7.6 Nasopharynglis 14.5 3.3 Piting adema 14.5 9.8 Skin lesion 14.4 8.7 Dyspnea exertional 14.1 0 Rash 14.1 0 Rash 14.1 0 Rash 14.1 9.8 Dijecton site reaction 13.6 0 Anxiely 13.2 3.3 Appetite decreased 12.7 4.3 Phyokalemia 12.7 4.3 URI 12.7 4.3 Degression 11.8 7.6 Productive cough 11.4 4.3 Insormia 10.9 4.3 Nataise 10.9 3.3 Preductive cough 10.5 3.3 Crackies lung 10.5 2.7 Sweating increased 10.5 2.7 Gradise murbur	Myalgia	15.9	2.2
Abdominal pain 15.5 13 Palor 15.5 7.6 Nasopharynglis 14.5 3.3 Pitting edema 14.5 9.8 Skin lesion 14.8 8.7 Dyspnea servitonal 14.1 16.3 Injection site bruising 14.1 0 Rash 14.1 9.8 Injection site reaction 13.6 0 Anxiety 13.2 3.3 Appetite decreased 12.7 4.3 Hypokalemia 12.7 4.3 URI 12.7 4.3 Protrutis 11.8 1.1 Depression 11.8 7.6 Productive cough 11.4 4.3 Malaise 10.9 4.3 Malaise 10.9 3.3 Preaumonia 10.9 3.3 Preaumonia 10.5 3.3 Crackise lung 10.5 2.2 Cardiae murmur 10 2.2 Cardiae m	Weight decreased	15.9	10.9
Pallor 16.5 7.6 Nasopharyngilis 14.5 3.3 Pitting edema 14.5 9.8 Skin lesion 14.4.8 8.7 Dyspnea exetional 14.1 16.3 Injection site bruising 14.1.1 9.8 Injection site reaction 13.6 0 Axweity 13.2 3.3 Appetite decreased 12.7 8.7 Fatigue aggravated 12.7 4.3 URI 12.7 4.3 URI 12.3 12 Abdominal tendemess 11.8 7.6 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Nataise 10.9 3.3 Preductive cough 10.5 3.3 Preductive cough 10.5 3.3 Crackles lung 10.5 3.3 Crackles lung 10.5 2.2 Ganomia tendemise 8.6 3.3 Crackles lung 8.6 3.3	Abdominal pain	15.5	13
Nasopharyngits 14.5 3.3 Pitting edema 14.5 9.8 Skn lesion 14.8 8.7 Dyspnea exertional 14.1 16.3 Injection site bruising 14.1 9.8 Injection site reaction 13.6 0 Anxiety 13.2 3.3 Appetite decreased 12.7 8.7 Fatigue aggravated 12.7 4.3 URL 12.3 12 Adominal tendencess 11.8 1.1 Depression 11.8 7.6 Productive cough 11.4 4.3 Insormia 10.9 4.3 Mataise 10.9 4.3 Productive cough 11.4 4.3 Mataise 10.9 3.3 Pealmonia 10.9 3.3 Preductive cough 10.5 3.3 Cracide murnu 10 2.2 Cardice murnu 10 2.2 Caridice murnu 10 2.2 <td>Pallor</td> <td>15.5</td> <td>7.6</td>	Pallor	15.5	7.6
Pitting edema 14.5 9.8 Dyspnea xentional 14.1 16.3 Dyspnea xentional 14.1 0 Rash 14.1 0 Rash 14.1 9.8 Injection site reaction 13.6 0 Anxiety 13.2 3.3 Appetite decreased 12.7 8.7 Falgue aggravated 12.7 4.3 Hypokalemia 12.7 4.3 URI 12.7 4.3 Pruritus 12.3 12 Adominal tenderness 11.8 1.1 Depression 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 5.4 Upper abdominal pain 10.5 8.7 Sweating increased 10.5 8.7 Sweating increased 10.5 8.7 Cardiac murmur 10 8.7 Rhinorthea 10 2.2 Cardiac murmur 10 8.7	Nasopharyngitis	14.5	3.3
Skin lesion 14.8 8.7 Dyspnea exertional 14.1 16.3 Injection site bruising 14.1 0 Rash 14.1 9.8 Injection site reaction 13.6 0 Anxiety 13.2 3.3 Appetite decreased 12.7 4.3 Hypokalemia 12.7 4.3 URI 12.7 4.3 URI 12.7 4.3 URI 12.7 4.3 Depression 11.8 7.6 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 3.3 Productive cough 10.5 3.3 Cracktes lung 10.5 2.2 Grade nummur 10 8.7 Sweating increased 10.5 2.2 Carlace nummur 10 8.7 Sweating increased 0.5 4.3 Upper abdominal pain 10.5 3.3	Pitting edema	14.5	9.8
Dyspne exertional 14.1 16.3 Injection site reaction 14.1 0 Rash 14.1 9.8 Injection site reaction 13.6 0 Anxety 13.2 3.3 Appelite decreased 12.7 8.7 Fatigue aggravated 12.7 4.3 Hypokalemia 12.7 4.3 VRI 12.7 4.3 Pruntus 12.7 4.3 Insomnia 10.9 4.3 Insomnia 10.9 4.3 Insomnia 10.9 5.4 Upper abdominal pain 10.5 8.7 Sweating increased 10.5 8.7 Sweating increased 10.5 3.3 Horps implay 9.5 4.3 Lymphadeno	Skin lesion	14.8	8.7
Injection site bruising 14.1 0 Rash 14.1 9.8 Injection site reaction 13.6 0 Anxiety 13.2 3.3 Appetite decreased 12.7 8.7 Failgue aggravated 12.7 4.3 Hypokalemia 12.7 4.3 UR 12.7 4.3 Depression 11.8 1.1 Depression 11.8 7.6 Productive cough 11.4 4.3 Insormia 10.9 4.3 Malaise 10.9 4.3 Productive cough 11.4 4.3 Insormia 10.9 4.3 Malaise 10.9 5.4 Upper abdominal pain 10.5 8.3 Crackes lung 10.5 8.7 Sweating increased 10.5 2.2 Gradea murmur 10 8.7 Rhimorthea 9.1 5.4 Upper abdominal pain 9.5 4.3	Dyspnea exertional	14.1	16.3
Rash 14.1 9.8 Injecton site reaction 13.6 0 Anxiety 13.2 3.3 Appetite decreased 12.7 8.7 Falgue aggravated 12.7 4.3 Hypokalemia 12.7 4.3 UR 12.7 4.3 Prufitus 12.7 4.3 Abdominal tendemess 11.8 1.1 Depression 11.8 1.1 Depression 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 5.4 Preumonia 10.9 5.3 Upper abdominal pain 10.5 3.3 Oracles lung 10.5 2.2 Cardiac murmur 10 8.7 Rhinorrhea 10 2.2 Ginglial bleeding 9.5 3.3 Herpes simplex 9.1 5.4 Heratorm 8.6 0 Night sweats 8.6 3.3 Rales	Injection site bruising	14.1	0
Injection 13.6 0 Anxiety 13.2 3.3 Appetite decreased 12.7 8.7 Fatgue aggravated 12.7 4.3 Hypokalemia 12.7 1.3 URI 12.7 4.3 Pruritus 12.3 12 Abdominal tendemess 11.8 1.1 Depression 11.8 7.6 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 4.3 Insomnia 10.9 5.4 Upper abdominal pain 10.5 8.7 Sweating increased 10.5 8.7 Carackes lung 0.5 4.3 Umper abdominal pain 10 8.7 Charking lung 10.5 8.3 Umper abdominal pain 10.5 8.3 Umphadenopathy 9.5 4.3 Herpes simplex 9.1 5.4 Herpes simplex 8.6 0	Rash	14.1	9.8
Anxiety 13.2 3.3 Appetite decreased 12.7 8.7 Falgue aggravated 12.7 4.3 Hypokalemia 12.7 4.3 UR 12.7 4.3 Pruritus 12.3 12 Abdominal tendemess 11.8 1.1 Depression 11.8 7.6 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 5.4 Openeosion 10.9 5.4 Upper abdominal pain 10.5 3.3 Grackes lung 0.0.5 2.2 Carackes lung 0.0.5 2.2 Carakites lung 9.5 3.3 Horperse 10 2.2 Ginglial bleeding 9.5 3.3 Herpes simplex 9.1 5.4 Herpes simplex 9.1 5.4 Herpes simplex 8.6 6.5 Vignada bleeding 7.7 1.1	Injection site reaction	13.6	0
Appetite decreased 12.7 4.3 Hypokalemia 12.7 13 UR 12.7 13 UR 12.7 13 UR 12.7 13 UR 12.7 13 Purdus 12.3 12 Abdominal tendemess 11.8 1.1 Depression 11.8 7.6 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 3.3 Preumonia 10.9 5.4 Upper abdominal pain 10.5 8.7 Sweating increased 10.5 8.7 Sweating increased 10.5 2.2 Cardiac murmur 10 8.7 Rhinorthea 10 2.2 Ingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 8.6 0 Nigit sweats 8.6 8.7 Tachycardia 8	Anxiety	13.2	3.3
Failgue aggravated 12.7 4.3 Hypokalemia 12.7 13 URI 12.7 4.3 Pruntus 12.3 12 Abdominal tendemess 11.8 1.1 Depression 11.8 1.1 Depression 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 3.3 Preunonia 10.9 3.3 Pneunonia 10.5 3.3 Crackles lung 10.5 8.7 Sweating increased 10.5 2.2 Cardiac murmur 10 8.7 Rhinorrhea 10 2.2 Gingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Lymphadenopathy 9.5 4.3 Lymphadenopathy 9.5 4.3 Lymphadenopathy 9.5 4.3 Lymphadenopathy 9.5 4.3 Upsit sweats 8.6 3.3 Rates<	Appetite decreased	12.7	8.7
Hypokalemia 12.7 13. Prufitus 12.7 4.3 Prufitus 12.3 12 Abdominal tendemess 11.8 1.1 Depression 11.8 7.6 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 3.3 Preumonia 10.9 3.3 Orackies lung 10.5 8.7 Sweating increased 10.5 8.7 Cardiac murrur 10 8.7 Rhinorthea 10 8.7 Rhinorthea 10 8.7 Ingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Herpes simplex 8.6 0 Night sweats 8.6 8.7 Tachycardia 8.6 2.2 Cellulitis 8.2 4.3 Organucosal petechiae 7.7 3.3 Stende	Fatigue aggravated	12.7	4.3
URI 12.7 4.3 Pruritus 12.3 12 Abdominal tendemess 11.8 1.1 Depression 11.8 1.1 Depression 11.8 7.6 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 5.4 Upper abdominal pain 10.5 3.3 Crackles lung 10.5 2.2 Cardiac nurmur 10 8.7 Rhinorrhea 10 2.2 Gingval bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Herpes simplex 9.1 5.4 Herpes simplex 9.1 5.4 Herpes simplex 8.6 3.3 Rates 8.6 6.5 Wheezing 8.6 2.2 Caliuitis 8.2 4.3 Dysuria 8.2 2.2 Caliuitis <	Hypokalemia	12.7	13
Pruntus 12.3 12 Abdominal tendemess 11.8 1.1 Depression 11.8 7.6 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 3.3 Pneumonia 10.9 3.3 Pneumonia 10.5 3.3 Crackles lung 10.5 8.7 Sweating increased 10.5 8.7 Cardiac murmur 10 8.7 Rhinorrhea 10 2.2 Gingvia bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Herpes simplex 9.1 5.4 Herpes simplex 8.6 3.3 Rales 8.6 3.3 Rales 8.6 2.2 Calultitis 8.2 2.2 Oral mucosal petechiae 7.7 1.1 Lethargy 7.7 0 Oral mucosal pete	URI	12.7	4.3
Abdominal tenderness 11.8 1.1 Depression 11.8 7.6 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 4.3 Preumonia 10.9 3.3 Pneumonia 10.9 5.4 Upper abdominal pain 10.5 3.3 Crackles lung 10.5 2.2 Cardiac murmur 10 8.7 Rhinorrhea 10 2.2 Gingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Herpes simplex 8.6 3.3 Vhoezing 8.6 3.3 Rates 8.6 8.7 Tachycardia 8.6 2.2 Cellulitis 8.2 2.2 Desting 7.7 1.1 Lymphadenopathy 9.3 3.3 Bingia bleeding 7.7 1.1 Cardiac mur	Pruritus	12.3	12
Depression 11.8 7.6 Productive cough 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 1.1 Pain 10.9 3.3 Pneumonia 10.9 3.3 Pneumonia 10.9 3.3 Upper abdominal pain 10.5 8.7 Sweating increased 10.5 8.7 Cardiac nurmur 10 8.7 Rhinorthea 10 2.2 Cardiac nurmur 10 8.7 Rhinorthea 10 2.2 Cardiac nurmur 10 8.7 Hemptes simplex 9.1 5.4 Hematoma 8.6 0 Night sweats 8.6 8.7 Tachycardia 8.6 2.2 Cellultis 8.2 4.3 Dysuria 8.2 2.2 Oral mucosal petechiae 7.7 1.1 Lethargy 7.7 0 Oral mucosal petechiae	Abdominal tenderness	11.8	1.1
Productive cough 11.4 4.3 Insomnia 10.9 4.3 Malaise 10.9 1.1 Pain 10.9 3.3 Pneumonia 10.9 5.4 Upper abdominal pain 10.5 3.3 Crackles lung 10.5 8.7 Sweating increased 10.5 2.2 Cardiac murmur 10 8.7 Rhinorrhea 10 2.2 Gingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Herpes simplex 9.1 5.4 Herpes simplex 8.6 3.3 Rales 8.6 3.3 Rales 8.6 3.3 Rales 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 3.3 Dyspepsia	Depression	11.8	7.6
Insomia 10.9 4.3 Malaise 10.9 1.1 Pain 10.9 3.3 Pneumonia 10.9 3.3 Crackles lung 10.5 3.3 Crackles lung 10.5 8.7 Sweating increased 10.5 2.2 Cardiac murmur 10 8.7 Rhinorrhea 10 2.2 Gingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Hematoma 8.6 0 Night sweats 8.6 3.3 Rales 8.6 6.5 Vheezing 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Oral mucosal petechiae 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 5.4 Dyspepsia 6.	Productive cough	11.4	4.3
Malaise 10.9 1.1 Pain 10.9 3.3 Pneumonia 10.9 5.4 Upper abdominal pain 10.5 3.3 Crackles lung 10.5 8.7 Sweating increased 10.5 2.2 Cardiac murmur 10 8.7 Rhinorrhea 10 2.2 Gingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Hernetoma 8.6 0 Night sweats 8.6 3.3 Rales 8.6 6.5 Yheezing 8.6 2.2 Celluititis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomattis 7.7 3.4 Peripheral swelling 7.3 5.4 Dyspepsia	Insomnia	10.9	4.3
Pain 10.9 3.3 Pneumonia 10.9 5.4 Upper abdominal pain 10.5 3.3 Crackles lung 10.5 8.7 Sweating increased 10.5 2.2 Cardiac murmur 10 8.7 Rhinorrhea 10 8.7 Cingival bieeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Hernes simplex 9.1 5.4 Hernes simplex 9.1 5.4 Hernetoma 8.6 0 Night sweats 8.6 3.3 Rales 8.6 8.7 Tachycardia 8.6 6.5 Wheezing 8.6 2.2 Oral mucosal petentiae 7.7 2.2 Oral mucosal petentiae 7.7 2.2 Oral mucosal petentiae 7.7 0 Urinary tract infection 7.7 2.4 Oral mucosal petentiae 6.8 1.1 Dyspepsia 6.8 4.3	Malaise	10.9	1.1
Pneumonia 10.9 5.4 Upper abdominal pain 10.5 3.3 Crackles lung 10.5 8.7 Sweating increased 10.5 8.7 Cardiac murmur 10 8.7 Rhinorrhea 10 2.2 Gingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Herpes simplex 9.1 5.4 Herpes simplex 8.6 3.3 Rales 8.6 3.3 Rales 8.6 8.7 Tachycardia 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Cellulitis 8.7 3.3 Dysuria 8.2 2.2 Oral mucosal petechiae 7.7 1.1 Lethargy 7.7 3.3 Otimatritis 7.7 0 Urinary tract infection 7.7 0 Urinary tr	Pain	10.9	3.3
Upper abdominal pain 10.5 3.3 Crackles lung 10.5 8.7 Sweating increased 10.5 2.2 Cardiac murmur 10 8.7 Rhinorrhea 10 2.2 Ginglval bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Herpes simplex 9.1 5.4 Herpes simplex 8.6 0 Night sweats 8.6 8.7 Rales 8.6 8.7 Cacluits 8.2 4.3 Dysuria 8.2 4.3 Dysuria 8.2 4.3 Dysuria 8.2 4.3 Oral mucosal petchiae 7.7 1.1 Lethargy 7.7 0 Urinary tract infection 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 6.8 4.3 Upspesia 6.8 0	Pneumonia	10.9	5.4
Crackles lung 10.5 8.7 Sweating increased 10.5 2.2 Cardiac murmur 10 8.7 Rhinorthea 10 2.2 Gingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Hematoma 8.6 0 Night sweats 8.6 3.3 Rales 8.6 3.3 Tachycardia 8.6 6.5 Whezing 8.6 2.2 Cellulitis 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 3.3 Oysuria 8.2 2.2 Breath sounds decreased 7.7 0 Urinary tract infection 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 6.8 0 Transfusion reaction 6.8 0 Transfusion reaction 6.8 0 <tr< td=""><td>Upper abdominal pain</td><td>10.5</td><td>3.3</td></tr<>	Upper abdominal pain	10.5	3.3
Sweating increased 10.5 2.2 Cardiac murmur 10 8.7 Rhinorrhea 10 2.2 Gingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Hematoma 8.6 0 Night sweats 8.6 8.7 Tachycardia 8.6 8.7 Tachycardia 8.6 8.7 Cellultis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 1.1 Injection site pruritus 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.4 6.5 Abdominal distension 5.9 3.3 <td>Crackles lung</td> <td>10.5</td> <td>8.7</td>	Crackles lung	10.5	8.7
Cardiac murmur 10 8.7 Rhinorrhea 10 2.2 Gingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Hematoma 8.6 0 Night sweats 8.6 3.3 Rales 8.6 3.3 Tachycardia 8.6 6.5 Whezzing 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Cellulitis 8.2 2.2 Oral mucosal petechiae 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 1.1 Injection site puritus 6.8 0 Transfusion reaction 6.8 0 Peripheral swelling 5.9 3.3	Sweating increased	10.5	2.2
Rhinorrhea 10 2.2 Ginglval bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Hematoma 8.6 0 Night sweats 8.6 3.3 Rales 8.6 3.3 Rales 8.6 8.7 Tachycardia 8.6 6.5 Wheezing 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.4 6.5 Abdominal distension 5.9 3.3	Cardiac murmur	10	8.7
Gingival bleeding 9.5 4.3 Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Hematoma 8.6 0 Night sweats 8.6 3.3 Rales 8.6 3.3 Tachycardia 8.6 8.7 Tachycardia 8.6 6.5 Wheezing 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 0 Urinary tract infection 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 0 Preipheral swelling 0 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 <t< td=""><td>Rhinorrhea</td><td>10</td><td>2.2</td></t<>	Rhinorrhea	10	2.2
Lymphadenopathy 9.5 3.3 Herpes simplex 9.1 5.4 Hematoma 8.6 0 Night sweats 8.6 3.3 Rales 8.6 3.3 Tachycardia 8.6 6.5 Wheezing 8.6 2.2 Celluititis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomattitis 7.7 5.4 Dyspepsia 6.8 4.3 Hemorhoids 6.8 4.3 Dyspepsia 6.8 0 Transfusion reaction 6.8 0 Transfusion reaction 6.8 0 Transfusion reaction 5.9 3.3 Muscle cramps 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Post procedural hemorrhage 5.9 3.3 <t< td=""><td>Gingival bleeding</td><td>9.5</td><td>4.3</td></t<>	Gingival bleeding	9.5	4.3
Herpes simplex 9.1 5.4 Hematoma 8.6 0 Night sweats 8.6 3.3 Rales 8.6 8.7 Tachycardia 8.6 6.5 Wheezing 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Post procedural hemorrhage 5.9 3.4 Urticaria 5.9 <t< td=""><td>Lymphadenopathy</td><td>9.5</td><td>3.3</td></t<>	Lymphadenopathy	9.5	3.3
Hematoma 8.6 0 Night sweats 8.6 3.3 Rales 8.6 8.7 Tachycardia 8.6 6.5 Wheezing 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 0 Urinary tract infection 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Abdominal distension 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Post procedural hemorrhage 5.9 2.2 Syncope 5.9 5.4 <td>Herpes simplex</td> <td>9.1</td> <td>5.4</td>	Herpes simplex	9.1	5.4
Night sweats 8.6 3.3 Rales 8.6 8.7 Tachycardia 8.6 6.5 Wheezing 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 0 Injection site pruritus 6.8 0 Transfusion reaction 6.4 6.5 Abdominal distension 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Post procedural hemorrhage 5.9 2.2 Syncope 5.9 3.3 Rhonchi 5.9 5.4 Urticaria 5.5 0 <td>Hematoma</td> <td>8.6</td> <td>0</td>	Hematoma	8.6	0
Rales 8.6 8.7 Tachycardia 8.6 6.5 Wheezing 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.4 6.5 Abdominal distension 5.9 3.3 Muscle cramps 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Rhonchi 5.9 3.3 Victaria 5.9 3.4 Muscle cramps 5.9 3.4 Dost procedural hemorrhage 5.9 3.4 <td>Night sweats</td> <td>8.6</td> <td>3.3</td>	Night sweats	8.6	3.3
Tachycardia 8.6 6.5 Wheezing 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Abdominal distension 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Rhonchi 5.9 5.4 Urticaria 5.9 5.4 Urticaria 5.9 3.3 Rhonchi 5.9 5.4 Losese stools 5.5 0	Rales	8.6	8.7
Wheezing 8.6 2.2 Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Abdominal distension 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Rhonchi 5.9 3.3 Rhonchi 5.9 5.4 Urticaria 5.9 5.4 Urticaria 5.9 3.3 Rhonchi 5.9 5.4 Urticaria 5.9 5.4 <t< td=""><td>Tachycardia</td><td>8.6</td><td>6.5</td></t<>	Tachycardia	8.6	6.5
Cellulitis 8.2 4.3 Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.4 6.5 Abdominal distension 5.9 3.3 Post procedural hemorrhage 5.9 1.1 Post procedural hemorrhage 5.9 3.3 Rhonchi 5.9 2.2 Syncope 5.9 5.4 Urticaria 5.9 5.4 Loose stools 5.5 0 Nasal congestion 5.5 0	Wheezing	8.6	2.2
Dysuria 8.2 2.2 Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Addominal distension 5.9 3.3 Post procedural hemorrhage 5.9 1.1 Post procedural hemorrhage 5.9 3.3 Rhonchi 5.9 2.2 Syncope 5.9 5.4 Uricaria 5.9 5.4 Loose stools 5.5 0 Nasal congestion 5.5 0	Cellulitis	8.2	4.3
Breath sounds decreased 7.7 1.1 Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Abdominal distension 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Rhonchi 5.9 3.3 Rhonchi 5.9 3.3 Rhonchi 5.9 5.4 Urticaria 5.9 5.4 Lose stools 5.5 5.4 Lose stools 5.5 0	Dysuria	8.2	2.2
Lethargy 7.7 2.2 Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Abdominal distension 5.9 3.3 Muscle cramps 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Rhonchi 5.9 3.3 Rhonchi 5.9 5.4 Urticaria 5.9 5.4 Urticaria 5.9 5.4 Lose stools 5.5 5.4 Lose stools 5.5 0	Breath sounds decreased	7.7	1.1
Oral mucosal petechiae 7.7 3.3 Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Abdominal distension 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Rhonchi 5.9 3.3 Urticaria 5.9 5.4 Urticaria 5.9 1.1 Anemia aggravated 5.5 5.4 Loose stools 5.5 0	Lethargy	7.7	2.2
Stomatitis 7.7 0 Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Abdominal distension 5.9 4.3 Muscle cramps 5.9 3.3 Post procedural hemorrhage 5.9 3.3 Post procedural hemorrhage 5.9 2.2 Syncope 5.9 5.4 Urticaria 5.9 5.4 Loose stools 5.5 0 Nasal congestion 5.5 1.1	Oral mucosal petechiae	7.7	3.3
Urinary tract infection 7.7 5.4 Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Abdominal distension 5.9 4.3 Muscle cramps 5.9 3.3 Post procedural hemorrhage 5.9 1.1 Postnasal drip 5.9 3.3 Rhonchi 5.9 2.2 Syncope 5.9 5.4 Urticaria 5.9 1.1 Anemia aggravated 5.5 5.4 Loose stools 5.5 0	Stomatitis	7.7	0
Peripheral swelling 7.3 5.4 Dyspepsia 6.8 4.3 Hemorrhoids 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Abdominal distension 5.9 4.3 Muscle cramps 5.9 3.3 Post procedural hemorrhage 5.9 1.1 Post procedural hemorrhage 5.9 3.3 Rhonchi 5.9 2.2 Syncope 5.9 5.4 Urticaria 5.9 1.1 Anemia aggravated 5.5 5.4 Loose stools 5.5 0	Urinary tract infection	7.7	5.4
Dyspepsia 6.8 4.3 Hemorrhoids 6.8 1.1 Injection site pruritus 6.8 0 Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Abdominal distension 5.9 4.3 Muscle cramps 5.9 3.3 Post procedural hemorrhage 5.9 1.1 Post procedural hemorrhage 5.9 3.3 Rhonchi 5.9 3.3 Rhonchi 5.9 2.2 Urticaria 5.9 5.4 Loose stools 5.5 0 Nasal congestion 5.5 1.1	Peripheral swelling	7.3	5.4
Hemorrhoids6.81.1Injection site pruritus6.80Transfusion reaction6.80Pleural effusion6.46.5Abdominal distension5.94.3Muscle cramps5.93.3Post procedural hemorrhage5.91.1Postnasal drip5.93.3Rhonchi5.92.2Syncope5.95.4Urticaria5.91.1Anemia aggravated5.55.4Loose stools5.50Nasal congestion5.51.1	Dyspepsia	6.8	4.3
Injection site pruritus6.80Transfusion reaction6.80Pleural effusion6.46.5Abdominal distension5.94.3Muscle cramps5.93.3Post procedural hemorrhage5.91.1Postnasal drip5.93.3Rhonchi5.92.2Syncope5.95.4Urticaria5.91.1Anemia aggravated5.55.4Loose stools5.50Nasal congestion5.51.1	Hemorrhoids	6.8	1.1
Transfusion reaction 6.8 0 Pleural effusion 6.4 6.5 Abdominal distension 5.9 4.3 Muscle cramps 5.9 3.3 Post procedural hemorrhage 5.9 1.1 Postnasal drip 5.9 3.3 Rhonchi 5.9 2.2 Syncope 5.9 5.4 Urticaria 5.9 1.1 Anemia aggravated 5.5 5.4 Loose stools 5.5 0 Nasal congestion 5.5 1.1	Injection site pruritus	6.8	0
Pleural effusion 6.4 6.5 Abdominal distension 5.9 4.3 Muscle cramps 5.9 3.3 Post procedural hemorrhage 5.9 1.1 Postnasal drip 5.9 3.3 Rhonchi 5.9 2.2 Syncope 5.9 5.4 Urticaria 5.9 1.1 Anemia aggravated 5.5 5.4 Loose stools 5.5 0 Nasal congestion 5.5 1.1	Transfusion reaction	6.8	0
Abdominal distension 5.9 4.3 Muscle cramps 5.9 3.3 Post procedural hemorrhage 5.9 1.1 Postnasal drip 5.9 3.3 Rhonchi 5.9 2.2 Syncope 5.9 5.4 Urticaria 5.9 1.1 Anemia aggravated 5.5 5.4 Loose stools 5.5 0 Nasal congestion 5.5 1.1	Pleural effusion	6.4	6.5
Muscle cramps 5.9 3.3 Post procedural hemorrhage 5.9 1.1 Postnasal drip 5.9 3.3 Rhonchi 5.9 3.3 Syncope 5.9 2.2 Urticaria 5.9 5.4 Loose stools 5.5 5.4 Nasal congestion 5.5 1.1	Abdominal distension	5.9	4.3
Post procedural hemorrhage 5.9 1.1 Postnasal drip 5.9 3.3 Rhonchi 5.9 2.2 Syncope 5.9 5.4 Urticaria 5.9 1.1 Anemia aggravated 5.5 5.4 Loose stools 5.5 0 Nasal congestion 5.5 1.1	Muscle cramps	5.9	3.3
Postnasal drip 5.9 3.3 Rhonchi 5.9 2.2 Syncope 5.9 5.4 Urticaria 5.9 1.1 Anemia aggravated 5.5 5.4 Loose stools 5.5 0 Nasal congestion 5.5 1.1	Post procedural hemorrhage	5.9	1.1
Rhonchi 5.9 2.2 Syncope 5.9 5.4 Urticaria 5.9 1.1 Anemia aggravated 5.5 5.4 Loose stools 5.5 0 Nasal congestion 5.5 1.1	Postnasal drip	5.9	3.3
Syncope 5.9 5.4 Urticaria 5.9 1.1 Anemia aggravated 5.5 5.4 Loose stools 5.5 0 Nasal congestion 5.5 1.1	Rhonchi	5.9	2.2
Urticaria 5.9 1.1 Anemia aggravated 5.5 5.4 Loose stools 5.5 0 Nasal congestion 5.5 1.1	Syncope	5.9	5.4
Anemia aggravated 5.5 5.4 Loose stools 5.5 0 Nasal congestion 5.5 1.1	Urticaria	5.9	1.1
Loose stools 5.5 0 Nasal congestion 5.5 1.1	Anemia aggravated	5.5	5.4
Nasal congestion 5.5 1.1	Loose stools	5.5	0
	Nasal congestion	5.5	1.1

May 2005

Atelectasis	5.0	2.2
Chest wall pain	5.0	0
Dry skin	5.0	1.1
Dysphagia	5.0	2.2
Injection site granuloma	5.0	0
Injection site pigmentation changes	5.0	0
Injection site swelling	5.0	0
Mouth hemorrhage	5.0	1.1
Tongue ulceration	5.0	2.2

*Nausea, vomiting, diarrhea, and constipation are dose related

Nausea, vomiting, injection site erythema, constipation, rigors, petechiae, injection site pain, dizziness, injection site bruising, anxiety, hypokalemia, insomnia, epistaxis, and rales tend to be more pronounced during the first 1-2 cycles. There were no cumulative adverse events.

Serious Adverse Events Resulting in Clinical Intervention

Discontinuation: leukopenia, thrombocytopenia, neutropenia

Dose Held: leukopenia, neutropenia, febrile neutropenia

Dose Reduced: leukopenia, neutropenia, thrombocytopenia

Common Adverse Events (Subcutaneous route)

Nausea, anemia, thrombocytopenia, vomiting, pyrexia, leukopenia, diarrhea, fatigue, injection site reaction, constipation, neutropenia, ecchymosis

Other Serious Adverse Events (<5%)

Blood: agranulocytosis, bone marrow depression, splenomegaly Cardiac: atrial fibrillation, cardiac failure, congestive failure, cardio-respiratory arrest, congestive cardiomyopathy GI: diverticulitis. GI hemorrhage, melena, perirectal abscess General: catheter site hemorrhage, general physical deterioration, systemic inflammatory response syndrome Hepatobiliary: cholecystitis Immune: anaphylactic shock, hypersensitivity Infection: limb abscess, bacterial infection, blastomycosis, injection site infection, Klebsiella sepsis, streptococcal pharyngitis, Klebsiella pneumonia, sepsis, Staph bacteremia, Staph infection, toxoplasmosis Metabolism: dehydration Musculoskeletal: aggravated bone pain, muscle weakness, neck pain Neoplasms: leukemia cutis Nervous system: convulsions, intracranial hemorrhage Psychiatric: confusion Renal: hematuria, loin pain, renal failure Respiratory: hemoptysis, lung infiltration, pneumonitis, respiratory distress Skin: pyoderma gangrenosum, pruritic rash, skin induration Vascular: orthostatic hypotension

Tolerability

Of the patients originally assigned to the azacitidine arm, 56% remained on active treatment by day 182 (6 months). At that time, 16% had died, and 22% had terminated therapy because of treatment failure, toxicity, or transformation to acute leukemia.

For further details on the safety results of the clinical trials, refer to *Appendix: Clinical Trials* (page 14).

May 2005

Precautions/Contraindications

Precautions

1. Blood counts should be performed periodically to monitor hematologic toxicity. At a minimum, counts should be performed before each dosing cycle. Dosing after the first cycle should be reduced or delayed based on nadir counts and hematologic toxicity if needed.

2. Safety and efficacy in patients with renal or hepatic insufficiency has not been studied.

3. Azacitidine is potentially hepatotoxic in patients with pre-existing severe hepatic impairment. Patients with extensive hepatic tumor burden have rarely experienced progression to hepatic coma and death during azacitidine therapy. This has occurred especially in patients with baseline serum albumins of <30g/dL. (See Contraindications)

4. Abnormalities ranging from increased serum creatinine to renal failure and death have rarely been reported in patients treated with IV azacitidine in combination with chemotherapy. Additional, renal tubular acidosis (a fall in serum bicarbonate to <20mEq/L with alkaline urine and hypokalemia) has been described in 5 patients with CML treated with azacitidine and etoposide. The dose of azacitidine should be reduced or held of unexplained reductions in serum bicarbonate to <20mEq/L or elevations in BUN or serum creatinine occur.

5. Since azacitidine and its metabolites are primarily excreted from the kidney, patients with renal impairment should be monitored closely. This includes geriatric patients who are more likely to have decreased renal function.

Use in Pregnancy: Pregnancy Category D

Use in Males: Men should be advised not to father a child during azacitidine therapy. In animal studies, azacitidine caused decreased fertility and loss of offspring during embryonic and postnatal development.

Contraindications

- 1. Patients with known hypersensitivity reactions to azacitidine or mannitol
- 2. Patients with advanced malignant hepatic tumors

Look-alike / Sound-alike (LA / SA) Error Risk Potential

The VA PBM and Center for Medication Safety is conducting a pilot program which queries a multi-attribute drug product search engine for similar sounding and appearing drug names based on orthographic and phonologic similarities, as well as similarities in dosage form, strength and route of administration. Based on similarity scores as well as clinical judgment, the following drug names <u>may</u> be potential sources of drug name confusion:

LA/SA for generic name azacitidine: cimetidine, famotidine, ranitidine, azathioprine, azulfidine, capecitabine, zalcitabine

Severity Category: minor-moderate

LA/SA for trade name Vidaza: Videx, Vitrase, Viadur

Severity Category: minor-moderate

Drug Interactions

Drug-Drug Interactions

No formal assessments have been conducted.

In vitro studies indicate azacitidine may be metabolized in the liver. The effect of hepatic enzyme inducers and inhibitors is unknown.

In vitro studies found that azacitidine does not induce CYP 1A2, 2C19, or 3A4/5.

May 2005

Acquisition Costs

Table #10	Azacitidine Costs			
Drug	Dose	Cost/Day/Cycle/patient (\$)	Cost/Year/patient (\$)	
Azacitidine	75mg/m ^{2/} /day for 7 days	555.92/3891.44	46,697.28	
Ana sitialized 400 mm viels EQC #077.00				

Tabla #40

Azacitidine 100mg vials FSS \$277.96

Pharmacoeconomic Analysis

There are no pharmacoeconomic studies of azacitidine in MDS.

Conclusions

Clinical Efficacy: Azacitidine produces response rates, measured using strict response criteria, in first line treatment of MDS that are statistically superior to best supportive care. In addition, a significant number of patients who did not meet the PR requirements were categorized as "improved", with mono- or bilineage response in blood counts or ≥50% decrease in transfusion requirements from baseline. In the area of timed events, azacitidine patients had a statistically significant delay in time to treatment failure, time to AML transformation, and time to death. In fact, this is the first drug used in MDS to delay and decrease transformation to AML. Overall survival showed a trend that favored azacitidine but was not statistically significant. This is confounded by the patients in the best supportive care arm who crossed over to azacitidine. In a landmark analysis of survival, patients initiated on the azacitidine arm had a statistically longer survival after the landmark date than patients who never crossed over or crossed over after the landmark date.

By definition, patients who achieved a CR or PR had an elimination of transfusion requirements for RBC's and platelets. Patients in the improved category also had improvement in transfusion requirements: 22% had elimination of all RBC transfusions, and 16% had a decrease of ≥50% in RBC transfusion requirements. In total, 45% of patients who were transfusion dependent at study entry had elimination of all transfusions and an additional 9% had a 50% reduction in transfusion requirements.

Quality of Life was measured on three scales assessing physical functioning, psychological well being, and patient's perception of well being. Azacitidine patients showed statistically significant improvement in fatigue, physical functioning, dyspnea, psychosocial distress, and positive affect. QoL scores were compared to performance status scores over time to test for clinical significance of improvement in QoL scores. In patients who completed the most QoL assessments (3 or 4 over 6 months), as QoL scores improved so did performance status scores.

There are questions about the study design. Although strict criteria were utilized to define complete and partial responses, the majority of the responses fell into the less strictly defined "improved" category. An analysis of only patients who met the CR or PR criteria was not performed. The second issue is the availability of crossover to azacitidine, especially once the phase II trial results were shown to be positive. It reduces the capacity to see significant differences in survival. Other randomization strategies may be needed in the future. The question of whether survival it the ultimate treatment endpoint in this and other cancers is still being debated. Although the studied regimen is active, other doses and schedules, as well as combination with cytokines and other signal modulators are areas of exploration.

Drug stability issues will make administration over 7 consecutive days in the ambulatory care arena difficult for some sites.

May 2005 Updated version may be found at www.pbm.va.gov or http://vaww.pbm.va.gov <u>Clinical Safety:</u> The most common adverse events were GI (nausea, vomiting, diarrhea) and myelosuppression. In early trials, the incidence of nausea and vomiting was the most common adverse events; in the majority of cases it was mild to moderate. In the registration trial, nausea and vomiting was reported in only 4% of patients, possibly due to better antiemetic regimens. Diarrhea is generally mild to moderate and controlled with standard antidiarrheals (loperamide). Myelosuppression is difficult to assess with standard criteria because MDS already causes profound cytopenias. In patients with profound baseline cytopenias it may be useful to assess relative changes in blood counts (e.g. a percent decrease from baseline values). Leukopenia, thrombocytopenia, and anemia were the most common reasons for discontinuation in therapy, dose reductions, and held doses. Blood counts should be monitored during therapy, at a minimum before the start of each cycle.

Azacitidine is potentially hepatotoxic in patients with severe pre-existing liver disease and in patients with significant metastatic disease to the liver. Hepatic transaminase elevations have been reported.

Injection site reactions were not reported in the registration trial, but were reported in another CALGB trial. They are generally mild and do not require further intervention in most cases.

Renal impairment may decrease excretion of azacitidine and its metabolites. Since geriatric patients are at risk for decreased renal function, they should be monitored carefully. A small number of cases of renal tubular acidosis have been reported.

Azacitidine can cause impairment of fertility and may cause fetal harm.

Most treatment related deaths were due to infection. The majority of deaths were due to disease transformation or progression.

Recommendations

Place in Therapy:

Myelodysplastic syndromes are a group of disorders of the bone marrow in which mature blood cells are produced from an abnormal clone cell. These abnormal clones eventually predominate in the bone marrow, which is less able to produce normal cells. It is characterized by bone marrow hyperproliferation and peripheral cytopenias, with signs and symptoms of fatigue, weakness, bleeding, infections, and anemia. Transformation to acute myelogenous leukemia occurs in 35-40% and it is often refractory to standard therapy. A number of chemotherapy drugs and cytokines have been studied in MDS, but none have altered the natural history of the disease. The standard of care is best supportive care with antibiotics and transfusions. The number of required RBC transfusions eventually leads to iron overload and the need for iron chelation therapy. Allogeneic bone marrow transplant is the only potentially curative approach, but is not a realistic option for the majority of patients.

Azacitidine is the first drug to provide clinical benefits to patients with MDS across a number of parameters when compared to best supportive care: increased response rate, delayed time to transformation to AML, decreased incidence of transformation to AML, decreased transfusion requirements, increased QoL, and a trend towards increased survival although not statistically significant.

Criteria for use should follow those in the phase III trial:

1. Patients with MDS. Those with RA or RARS in addition should have one of the following: symptomatic anemia requiring transfusions for at least the past 3 months, or thrombocytopenia with a platelet count $\leq 50 \times 10^{9}$ /L or significant clinical hemorrhage requiring platelet transfusion, or neutropenia with an ANC< 1 x 10⁹/L requiring IV antibiotics.

2. Performance Status ≤2

3. Total bilirubin ≤1.5 X ULN

May 2005

4. AST/ALT ≤1.5 X ULN

5. Serum creatinine ≤1.5 X ULN

6. Serum bicarbonate ≥19mEq/L

7. No previous treatment for MDS with chemotherapy drugs or cytokines within 7 days except epoetin.

8. No history of leukemia

9. No pregnancy or uncontrolled CHF

As the only treatment besides best supportive care for MDS, recommend adding azacitidine to the national formulary.

Prepared Mo/Yr. Contact person: Name, Title(s)

Mark C. Geraci, Pharm.D., BCOP

Clinical Specialist, VHA Pharmacy Benefits Management Strategic Healthcare Group April 2005

References

¹ Product Package Insert. VidazaTM. Pharmion Corporation, Boulder, Colorado. May 2004.

² Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5azacytidine, VidazaTM) for injectable suspension. The Oncologist 2005;10:176-182.

³ Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharamcol 2005;45:597-602.

⁴ Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20:2429-2440.

⁵ Kornblith AB, Herndon JE, Lilverman LR, Demakos EP, Odchimar-Reissig R, et al. Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol 2002;20:2441-2452.

Appendix: Clinical Trials

A literature search was performed on PubMed/Medline (1966 to April 2005) using the search term azacitidine. The search was limited to studies performed in humans and published in English language. Reference lists of review articles and the manufacturer's AMCP dossier were searched for relevant clinical trials. All randomized controlled trials published in peer-reviewed journals were included.

Appendix Table: Azacitidine clinical trials

Citation													
Design													
Analysis													
type	Eligibility		Patient Population Profile			Efficacy Results							
Setting	Criteria	Interventions								Safety Results			
Silverman	Inclusion criteria	A. Azacitidine	N=191			Result	AzaC	aC BSC Cross-		Most common: myelosuppression			
2002	1. FAB	75mg/m ²							over	Difficult to assess using standard criteria			
CALGB	classification	subcutaneously	AzaC BSC						N=49	because the disease	because the disease causes severe		
9221	criteria for MDS	daily for 7 days,		N=99	N=92	CR	7%*	0%	10%	cytopenias			
Phase III	2. For RA or	repeat every 28	FAB			PR	16*	0	4				
	RARS additional	days + best	RA	17	20	Improved 37* 5† 33 Grade 3 or 4 Hen			Grade 3 or 4 Hematol	atologic I oxicity			
	criteria: at least 1	supportive care	RARS	5	3	Total	60*	5	47	Cytopenia	Standard	Relative	
	of the following:	(transfusions,	RAEB	32	34	Trilineage					Criteria	Criteria	
	symptomatic	antibiotics,	RAEBT	27	18	Response	23	0	14	Leukopenia	59%	43%	
	anemia requiring	hospitalizations)	CMMoL	7	7	Response to AzaC was independent of		Granulocytopenia	81%	58%			
	transfusions for at		Other	11	10	MDS classific	cation			Thrombocytopenia	70%	52%	
	least 3 months,	st 3 months, B. Best Supportive Age 69 67 † all 5 pat					† all 5 patients had improved counts			Toxicity was transient and usually recovered			
	thrombocytopenia	Care (BSC)	Male	72	73	while transfor	ming to	ÁML		by the next cycle			
	with 2 or more	th 2 or more (crossover to Bleeding 16 18 *differences in arm				n arms ir	n CR ra	rate					
	counts ≤50 x	azacitidine allowed	Platelet	18	10	(P=0.01), CR+PR (P<0.0001),			Treatment-related infection in 20%				
	10°/L with clinical	after a minimum of 4	Transfusion			CR+PR+improvement (P<0.0001)							
	hemorrhage	months)	RBC	68	56	Timed Analyses (median) Event AzaC BSC			Nausea or vomiting in 4%.				
	requiring		transfusion										
	transfusion, or								1 treatment related death				
	neutropenia and					TT initial	64 day	s -					
	infection requiring					response							
	IV antibiotics					TT best	93 day	s -					
	3. PS ≤2					response							
	4. T.bili ≤1.5 x					Duration	15	-					
	ULN					of	months	;					
	5. AST/ALT≤2 x					response							
	ULN					TTF	9.1 mo	s* 3	.8 mos				
	6. S. creatinine					TT AML	21 mos	** 1	2 mos				
	≤1.5 x ULN					or death							
	7. S. CO₂ ≥19					AML as	15%†	3	8%				
	mEq/L					first event		Ũ					
	8. No previous					Overall	20 mos	t 1	4mos				
	treatment for					survival		· ·					
	MDS with Aza C.					*P<0.0001 **P=0.007 +P=0.001							
	GCSF, GMCSF,	GCSF, GMCSF,					+P=0 1						
	or other cytokines					+ 0.1							
	except epoetin												
	No epoetin,												

May 2005

Updated version may be found at www.pbm.va.gov or http://www.pbm.va.gov

Citation Design						
Analysis						
type	Eligibility			Efficacy Results		
Setting	Criteria	Interventions	Patient Population Profile	<u> </u>		Safety Results
	corticosteroids,			Landmark survival	analysis	
	Interreron, or					
	reunoids w/r r			Subgroup	Survival	
	10 No history of			BSC patients	11 months	
	leukemia			who never		
	11 No pregnancy			crossed over of		
	or uncontrolled			after 6 months		
	CHF			BSC nationts	14 months	
	0.11			who crossed		
				over before 6		
				months		
				Patients initially	18 months	
				randomized to	(p=0.03	
				Azacitidine	compared to	
					group who	
					never crossed	
					over or crossed	
					over late)	
				Landmark AML tra (12 month Landma	nsformation analysis rk date)	
				Subaroup	Additional	
				0 1	Survival	
				Transformed to	3 months	
				AML before	(95%CI 1-11)	
				landmark date		
				N=13		
				Had not yet	18 months	
				transformed to	(95%CI 14-26)	
				AML by	p<0.001	
				landmark date		
				N=93		
				Effect on RBC's an	d platelets	
				Effect	AzaC	
				RBC lineage	51%	
				response		
				Elimination of	45%	
				RBC transfusion		

Citation Design Analysis type Setting	Eligibility Criteria	Interventions	Patient Population Profile	Efficacy Results		Safety Results	
				Reduce RBC transfusion by 50%	9%		
				Platelet	47%		
				response			
				WBC response	40%		
				Quality of Life Ana	ysis AzaC vs BSC		
				QoL Parameter	P value		
				Fatigue	0.001		
				Dyspnea	0.0014		
				Physical	0.002		
				function			
				Positive affect	0.0077		
				Psychological	0.015		
				distress			

FAB=French-American-British; MDS=myelodyplastic syndrome; RA=refractory anemia; RARS=refractory anemia with ringed sideroblasts; PS=performance status' T. bili= total bilirubin; ULN=upper limits of normal; AzaC=azacitidine; RAEB=refractory anemia excessive blasts; RAEB-T=refractory anemia excessive blasts in transformation to leukemia; CMMoL=chronic myelomonocytic leukemia; CR=complete response; PR=partial response; RBC=red blood cell, TT initial response=time to initial response; TT best response=time to best response; TTF=time to treatment failure; AmIm=acute myelogenous leukemia; WBC=white blood cell